Speakers:
Todd A. Mahr, MD, FACAAI
David R. Stukus, MD, FACAAI
Mrs. Patricia Wedner, Alliance President

The 2019 Gold Headed Cane Award will be presented at this time to Dana V. Wallace, MD, FACAAI.

This session will address the evolution of evidence pertaining to conditions for which allergists play a central role in management. Attendees will hear discussion surrounding new guidelines, new conditions and new approaches to longstanding beliefs.

Moderator: Todd A. Mahr, MD, FACAAI, ACAAI President

Bring your passport game card for a chance to win!

Booth #613

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Supported by AstraZeneca

Not For Credit

Presented by:
Reynold A Panettieri, MD

This program will examine the relationship between shortacting 2-agonist (SABA) reliance, patient behavior, and asthma morbidity. An understanding of SABA reliance and its consequences highlights an unmet need and an opportunity to optimize control.

Also visit AstraZeneca at Booth #301.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Not For Credit

Presented by:
Neal Jain, MD

Listen to an expert clinician discussion an add-on maintenance treatment for patients with moderateto- severe asthma aged 12 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma. Our presenter will highlight key roles for Type 2 Inflammation in the pathobiology of asthma and the efficacy and safety data across three clinical trials in nearly 3,000 patients with asthma. Additionally, our presenter will lead an interactive discussion of different patient types who might be eligible for treatment.

Also visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313.

Supported by GlaxoSmithKline

Not For Credit

Presented by:
Dennis K. Ledford, MD

Join us for an engaging program exploring the role of eosinophils in disease management. We will examine key efficacy and safety data for a treatment that reduces eosinophils, including long-term data in patients with severe asthma. We will also discuss clinical approaches for identifying appropriate patient types that may benefit from a targeted treatment to reduce eosinophils.

Also visit GlaxoSmithKline at Booth #1012.

Invitation only. All division directors and training program directors are invited.

This panel discussion is a program of the Joint Task Force on Academic Allergy/Immunology, which was created to evaluate needs and develop tools and strategies to support the success of academic allergy/immunology divisions. The interactive session will discuss challenges and opportunities facing A/I divisions within academic medical centers. There will be opportunity for significant audience involvement to discuss challenges, successes and opportunities at your center with other academic leaders.

Moderator: Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

Supported by an independent educational grant from Teva Pharmaceuticals

Despite advances in pharmaceutical management of asthma, patients continue to have high frequency of health care utilization due to poor control of asthma symptoms and frequent exacerbations. Many factors are thought to contribute to this, with poor adherence to medical treatment felt to be a major factor. Adherence to asthma medications has historically been very poor, particularly with inhaled medications. Also, poor recognition of symptoms has frequently been found in a subset of patients with chronic asthma, leading to poor outcomes. Digital technology has the opportunity to address many of these issues. Mobile apps are being developed specifically for patients with asthma, including both educational and self- and remote-monitoring functions. New inhalers are being developed that contain chips to provide real-time feedback at the time of use. Digital technology has the opportunity to reduce health and social inequities incurred by the disease.

Moderators: Jared Darveaux, MD, and Mark C. Stahl, DO, FACAAI

ARS

Multiple new studies have been published that show the potential benefit of specific interventions in preventing the development of atopic dermatitis and food allergies. Allergists need to remain at the forefront of this research and understand how to implement evolving data into clinical practice. This session will utilize case-based discussions to review the most up-to-date evidence and provide practical talking points to help educate parents and primary care providers.

Moderators: Angela D. Hogan, MD, FACAAI, and Bruce J. Lanser, MD, FACAAI

Oral food challenges are the gold standard to diagnose food allergy. However, oral food challenges are underutilized in clinical practice. This session will address the challenges of implementing oral food challenges into clinical practice, with particular focus on performing food challenges in infants, as well as a review of anaphylaxis management in infants.

Moderators: Anne K. Ellis, MD, MSc, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

ARS MOC/CME

From skin-deep to outward, this session will discuss the etiology, management and evaluation of patients with severe cutaneous drug eruptions.

Moderators: Leonard Bielory, MD, FACAAI, and Joseph A. Bellanti, MD, FACAAI

Bring your passport game card to the Exhibit Hall for a chance to win!

Supported by Aimmune Therapeutics

Not For Credit

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Not For Credit

Not For Credit

Looking for new opportunities, an associate for your group or a buyer for your practice? The Doctors’ Job Fair brings together all interested parties seeking or offering professional opportunities.

Supported by AstraZeneca

Not For Credit

Presented by:
Warner Carr, MD

Please join us to learn more about ways to help identify eosinophilic asthma through a combination of clinical features, patient history and measurements of eosinophils told through three compelling patient case studies. Hosted by a national expert, explore a targeted treatment approach for patients with both efficacy and safety profile data.

Also visit AstraZeneca at Booth #301.

Supported by CSL Behring

Not For Credit

Presented by:
Raffi Tachdjian , MD, MPH
Zahra Khan (HAE Patient Advocate)

Join us as we present newly published data from the Open Label Extension Study following patients long term. Hear from an HAE opinion leader and an HAE patient as they talk about the impact of HAE and successfully managing the disease.

Also visit CSL Behring at Booth #123.

Supported by Novartis Pharmaceuticals Corporation

Not For Credit

Allergic asthma is a specific phenotype of a common disease with wide heterogeneity. Associated comorbidities often go hand-in-hand with the condition. Such comorbidities may share common immunopathological mechanisms with asthma that can influence its control. Immune Response Pathways: Characteristics of Asthma and Comorbidities will focus on the immune response of allergic asthma, accurate recognition of these characteristics and proper management of comorbidities.

Also visit Novartis Pharmaceuticals Corporation at Booth #1213.

Not For Credit

ACAAI, ABAI and diplomates are key stakeholders in the current transformation of allergy/immunology continuing certification. This session will provide attendees an overview of the current landscape of continuing board certification, an update on the continuous assessment program (CAP) and personal progress meter. An interactive town hall will be held during this session, as part of ABAI’s commitment to co-development of specialty-continuing certification.

We have an expanding supply of tools for managing the noninfectious complications of CVID. Understanding the availability and utility of these tools will help practitioners in the diagnosis and treatment of the noninfectious complications of CVID.

Moderators: Nikita Raje, MD, FACAAI, and Benjamin Prince, MD, MSci

MOC/CME

Several new interventions are likely to be approved by the FDA in the upcoming year. These therapies have different levels of efficacy and side effects and will likely greatly impact office flow. Thus, it is imperative that allergists become more facile with their knowledge regarding these therapies.

Moderators: John J. Oppenheimer, MD, FACAAI, and Marcus Shaker, MD, MSc, FACAAI

The healthy allergy and immunology clinic involves more than just keeping the schedule full. An unhealthy clinic can contribute to the allergist’s stress level, burnout and depression, as well as poor patient satisfaction, compliance and outcomes. In this session, find out what constitutes an unhealthy work environment in the clinic and learn how to use the principles of integrative medicine to improve the health of the clinic and, consequently, of our patients and ourselves as providers.

Moderators: Janna M. Tuck, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI

COPD is the third leading cause of death in the United States, and our specialty is encountering both diagnosed and undiagnosed COPD patients at an increased rate. Allergy/immunology specialists are in a unique position to be at the forefront of COPD care, including evaluating potential immune deficiencies in this patient population. In addition, many patients may have asthma-COPD overlap (ACO), and there is still considerable debate in the medical community regarding the exact diagnosis and treatment of this condition.

Moderators: Anil Nanda, MD, FACAAI, and Michael B. Foggs, MD, FACAAI

This session will provide the allergist/immunologist a perspective on the diversity of food allergy along racial, ethnic and socioeconomic lines. There will be particular focus on associations with morbidity and mortality, what diverse families may value regarding food allergy, how they may choose to spend their health care dollars and how this may differ from the primarily white, middle class families typically described in food allergy.

Moderators: Cherie Y. Zachary, MD, FACAAI, and Princess Ogbogu, MD, FACAAI

Limit 45. Seats Available on first-come, first-served basis.

These expert round table discussions will address some of the threats and potential pitfalls of allergy practice today. Choose three of the five topics and spend 25 minutes with each expert addressing a phase of allergy practice. The expert will give a five-minute overview of the topic and will then answer questions and facilitate discussion with the table participants for 20 minutes.

Table Rotations: 1:05 pm, 1:30 pm, 2:00 pm

Moderator: Warner W. Carr, MD, FACAAI

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Not For Credit

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Supported by Optinose

Not For Credit

Presented by:
Shahnaz Fatteh, MD

Explore a unique patient case to understand how XHANCE is a different treatment approach.

Also visit Optinose at Booth #1021.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Not For Credit

Presented by:
Eli O. Meltzer, MD

Please join Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. for a Product Theater presentation at the ACAAI Conference, located on the exhibit floor. Food and beverage to be served.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., Booth #313

ARS

This session will address cannabis legalization and patient perceptions and patterns of use. We will discuss how cannabis is commonly used, review the importance of asking our patients about cannabis use, the effects of cannabis on the lungs (also versus tobacco) and review allergic sensitization to cannabis. Common misconceptions will be discussed, including the ideas that cannabis is “good” for asthma, that it is safer than tobacco, that it is not addictive and that cannabis allergy does not exist. Attendees will gain a greater understanding of cannabis and its effects, so they can instantly bring this knowledge to their clinical practice in order to empower their patients and advocate for their well-being.

Moderators: William S. Silvers, MD, FACAAI, and Michael R. Rupp, MD, FACAAI

This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for 2019 and the AMA’s outlook for medicine. This will be accomplished by practical case-based scenarios focused on how the change may affect the practice of allergy and clinical immunology. In addition, we’ll review the state of politics and the national perspective of medicine as seen through the eyes of the AMA. Finally, we’ll offer an update on the changing landscape on Capitol Hill as it relates to the current state of government.

Moderators: James M. Tracy, DO, FACAAI, and Stephen A. Imbeau, MD, FACAAI

Supported by an independent educational grant from Merck & Co., Inc.

Cough is one of the most common symptoms of patients seen by allergist/immunologists. Understanding the mechanisms that lead to cough is paramount. A new paradigm has emerged of patients with cough (neural) hypersensitivity that does not respond to asthma, rhinitis and/or GERD therapy. Allergists need to understand the different therapeutic agents and their mechanisms of action in all stages of cough.

Moderators: Jeremy S. Katcher, MD, FACAAI, and J. Wesley Sublett, MD, MPH, FACAAI

A recording of this session will be available after the Annual Meeting on the College Learning Connection.

Supported by an independent educational grant from Abbvie

This session will consider treatment of the itch in persons with atopic dermatitis. Should allergists prescribe monoclonal antibodies or drugs that block neurotransmitters?

Moderators: Myron J. Zitt, MD, FACAAI, and Allison C. Ramsey, MD, FACAAI

This session will review the newly published jointly developed AGA/AAAAI/ACAAI GRADE-based EoE guidelines discussing the new clinical recommendations and areas of emerging evidence. There will be particular emphasis on how the allergist and gastroenterologist can co-manage this illness.

Moderators: John J. Oppenheimer MD, FACAAI, and Dana V. Wallace, MD, FACAAI

Not For Credit

Moderators: Brian T. Kelly, MD, FACAAI, and David R. Stukus, MD, FACAAI

Not For Credit

Moderators: Lisa J. Kobrynski, MD, MPH, FACAAI, and Janna M. Tuck, MD, FACAAI

Supported by DBV Technologies

Not For Credit

Test your knowledge, sharpen your wits and join in the fun at the dynamic, fast-paced FIT Bowl! Participating teams from training programs around the country will compete to answer a variety of serious (and not so serious) questions posed by an expert panel. Approximately 30 teams from the US and Mexico will participate in this popular game show.

Supported by Teva Pharmaceuticals

Not For Credit

Presented by:
Gregory W. Bensch, MD
Nabeel Farooqui, MD
Warner W. Carr, MD
Maeve O’Connor, MD

Join an expert panel for an interactive program about the use of digital technology and the role of objective inhaler use data in asthma patient care. Learn about how inhaler use data may inform patient consultations. Attendees may also engage in a hands-on demonstration of an e-connected inhaler.

Also, visit Teva Pharmaceuticals at Booth #113.

Supported by Genentech and Novartis Pharmaceuticals Corporation

Not For Credit

Presented by:
Thomas B. Casale, MD
Jonathan Corren, MD

Test your asthma knowledge! The Allergic Asthma Challenge gives you an opportunity to compete against your colleagues in a trivia format. Questions and educational content will focus on asthma phenotypes and endotypes, asthma biomarkers, and the role of IgE in allergic asthma. We look forward to seeing you there!

Also, visit Genentech and Novartis Pharmaceuticals Corporation at Booth #713.

Supported by GlaxoSmithKline

Not For Credit

Presented by:
Nicola Hanania, MD
Nestor Molfino, MD

Eosinophils play an important role in airways inflammation and proposed phenotypes in asthma and COPD. This program will review the biology of eosinophils and cellular-mediated mechanisms of airway inflammation. Use of eosinophils to identify subpopulations as well as guideline recommendations for incorporation of phenotyping into clinical practice will be highlighted.

Also, visit GlaxoSmithKline at Booth #1012.